Clarivate posts Q3 loss, beats EPS, but revenue miss follows Life Sciences divestiture
Clarivate Plc released its third‑quarter 2026 results, showing total revenue of $567.9 million including the Life Sciences & Healthcare segment and $481.6 million after excluding that business, which was sold on October 6, 2026. Organic revenue for the continuing operations grew 0.4% year‑over‑year, while the company recorded a net loss of $80.8 million, or $0.13 per diluted share. Adjusted earnings per share were $0.21, topping forecasts, and the firm updated its full‑year outlook with revenue now expected around $1.97 billion.
Why it matters
The revenue shortfall, highlighted by the company’s own guidance, suggests lower top‑line growth than analysts had projected, which may pressure the stock price. However, the earnings beat and continued organic ACV growth indicate that the core subscription model remains resilient, according to management’s commentary.
Key facts
- 1Total revenue for the quarter was $567.9 million, including the Life Sciences & Healthcare segment. prnewswire.com
- 2Revenue excluding the divested segment was $481.6 million. prnewswire.com
- 3Organic revenue for continuing operations increased 0.4% year‑over‑year. prnewswire.com
- 4The company posted a net loss of $80.8 million, or $0.13 per diluted share. prnewswire.com
- 5Adjusted net income was $136.0 million, or $0.21 per diluted share. prnewswire.com
- 6Adjusted EBITDA for the quarter was $245.3 million. prnewswire.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.